Skip to main content
MyDeficiencies

Desvenlafaxine

Serotonin-norepinephrine reuptake inhibitor (SNRI), "other antidepressants" group; the major active metabolite of venlafaxine

Also sold as Pristiq.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Desvenlafaxine has exactly one labeled, depletion-adjacent mechanism, dilutional hyponatremia from SIADH, and no classical absorption-interference, enzyme-induction, or renal-wasting mechanism against any other nutrient. Its pharmacokinetics are genuinely simpler than its parent compound's: desvenlafaxine is "primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism" via CYP3A4 N-demethylation, and its own label states plainly that "the CYP2D6 metabolic pathway is not involved" and that "the pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype." This is the opposite pattern from venlafaxine, whose conversion to desvenlafaxine (its active metabolite) is itself CYP2D6-dependent and therefore variable across metabolizer phenotypes. Desvenlafaxine does not inhibit or induce CYP3A4 or any other major CYP isozyme tested, is not a substrate or inhibitor of P-glycoprotein, and a dedicated in vitro comparison found that "venlafaxine, and to a lesser extent desvenlafaxine" induced the drug-efflux transporters P-glycoprotein and BCRP in human brain microvascular endothelial cells, with a separate, earlier study from the same group finding venlafaxine but not desvenlafaxine induced this effect at all. Approximately 45% of a desvenlafaxine dose is excreted unchanged in urine, a far higher fraction than venlafaxine's roughly 5%, reflecting how much less biotransformation desvenlafaxine itself undergoes. None of this PK profile implies chelation, gastric-pH change, bile-acid sequestration, or accelerated catabolism of a nutrient; conjugation via UGT isoforms is a high-capacity pathway with no cofactor-depletion mechanism established in this review, unlike, for example, glycine or glutathione conjugation elsewhere in pharmacology, so this mechanism (present in form) is not carried forward as a nutrient-depleting one. What the label does state directly, in language essentially identical to venlafaxine's own, is that "hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ... in many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)," with cases of serum sodium below 110 mmol/L reported and elderly, diuretic-treated, or volume-depleted patients at greatest risk.

Serotonin-norepinephrine reuptake inhibitor (SNRI), "other antidepressants" group; the major active metabolite of venlafaxine · ATC N06AX23 · also sold as Pristiq (original brand); generic desvenlafaxine extended-release tablets widely available · reviewed 2026-09-29. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Desvenlafaxine in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Sodium, SIADH-mediated dilutional hyponatremia

Orange — Moderate

See study details

Desvenlafaxine's own label documents hyponatremia, usually via SIADH, with cases of serum sodium below 110 mmol/L, and this review located two published case reports naming desvenlafaxine specifically, but no dedicated human cohort or case-control study stratified to desvenlafaxine was located, so this is graded orange, not red, unlike the companion venlafaxine dossier's red grade for the same mechanism.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Key negative/null findings: No study located in this review found desvenlafaxine free of hyponatremia risk relative to no antidepressant use; the gap here is the absence of a quantified cohort estimate specific to desvenlafaxine, not a contradicting finding. A dedicated PubMed search combining "desvenlafaxine" and "hyponatremia" returned exactly four results (the three sources above plus the Garakani tramadol case), none of which was a cohort or case-control design with a computed effect estimate for desvenlafaxine alone.
  • At-risk subgroups: Elderly patients; patients on diuretics or otherwise volume-depleted, per the label, identical to venlafaxine's labeled risk factors.

Regulatory status

FDA label, Section 5.9, verbatim: "Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)... Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk." Signs and symptoms listed include "headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls," with more severe cases including "hallucination, syncope, seizure, coma, respiratory arrest, and death."

Population evidence

Lee GT, Leung JL, "Syndrome of Inappropriate Secretion of Antidiuretic Hormone due to Desvenlafaxine," General Hospital Psychiatry 2013, confirmed via PubMed search-listing (title, authors, journal, year), described in the listing as "the first case in which desvenlafaxine-associated SIADH was reported," full text not opened during this review. Liew ED, Alderman CP, "Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Desvenlafaxine," International Journal of Clinical Pharmacy 2014, confirmed via PubMed search-listing, a case report in a 57-year-old female patient, full text not opened during this review. Viramontes TS, Truong H, Linnebur SA, "Antidepressant-Induced Hyponatremia in Older Adults," The Consultant Pharmacist 2016, a narrative review (Tier C, not drug-level stratified beyond naming desvenlafaxine among the antidepressants discussed), confirmed via PubMed search-listing. Also identified via search but of uncertain direct relevance and not used as supporting evidence: Garakani A, "Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine," Primary Care Companion for CNS Disorders 2018, a case report where tramadol, not desvenlafaxine alone, is identified in the title as the primary suspected cause, noted here as unverified context only.

Mechanism

Serotonergic and noradrenergic potentiation of antidiuretic hormone (vasopressin) release and renal free-water retention, producing a dilutional fall in serum sodium (SIADH pattern). This is a retention/dilutional disturbance, not a dietary sodium deficiency, and is mechanistically identical to venlafaxine's own labeled mechanism, consistent with desvenlafaxine being venlafaxine's active metabolite and principal circulating serotonergic/noradrenergic moiety.

Counter-evidence held on record

This entry is bounded specifically by the absence of a dedicated human cohort or case-control study naming desvenlafaxine, in contrast to venlafaxine's companion dossier; the mechanism itself (SIADH, drug-class labeled) is not in doubt, only the strength and quantification of desvenlafaxine-specific population evidence located in this review. This is a dilutional/retention electrolyte disturbance, not a dietary sodium deficiency, and nothing here implies sodium or fluid supplementation as a remedy; the clinical response to significant hyponatremia is fluid restriction, dose adjustment, or discontinuation under medical supervision, and increasing sodium intake around desvenlafaxine use is not supported by this entry.

No category qualifies as ungraded

Not graded — disclosed evidence gap

See study details

Every one of the seven required physiological categories, and the one classical nutrient carried forward from the mechanism screen (sodium), reached at least a yellow grade in this review, though five of the seven required categories reached that grade only through disclosed class/metabolite extrapolation from venlafaxine, not through desvenlafaxine-specific evidence.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. not applicable

Limits on what this shows

  • Why no grade is empty: Ungraded requires both no Tier B/C evidence to support even yellow and no circulating claim to rebut as white. For every category graded above, this review located either genuine desvenlafaxine-specific Tier B evidence (Sodium, Oxidative stress, and the motility component of Gut microbiome risk) or a real, drug-specific Tier B/A venlafaxine finding usable as Tier C class/metabolite extrapolation (Oxygen delivery/utilization, Mitochondrial burden, ATP production, Copper, Iron), consistent with this project's rule that a real class member's data is sufficient to avoid an ungraded status even when the target drug itself has no direct evidence. This should not be read as reassurance that these five categories are settled for desvenlafaxine; they are exactly the categories where this review most wants a future revision to search again once desvenlafaxine accumulates more of its own dedicated literature.

Channels tried across all categories

PubMed search-listing pages (reliable for the large majority of attempts, used extensively, with intermittent reCAPTCHA bot-verification challenges on individual article pages); the Crossref API (reliable for bibliographic and abstract-level confirmation, used extensively after PubMed rate-limiting); the OpenAlex API (used successfully at least once for abstract-level detail, otherwise frequently rejected); the Europe PMC REST API and Semantic Scholar Graph API (returned HTTP 429 rate-limit responses or proxy-level 403 rejections on nearly every attempt across this review, for every category, not just one); DailyMed and accessdata.fda.gov (reliable, used extensively for the label); drugs.com and RxList (reliable, used for the circulating-claim audit and for cross-checking the Oxygen delivery/utilization entry's absence of hematologic content). This review's WebSearch tool allowance was exhausted before a small number of secondary confirmatory queries (including a brand-name history check) could be completed.

Genuine gap vs. tooling-limited

Not applicable here since no category was left ungraded, but this row is printed to state plainly, per this project's rule, that the absence of an ungraded entry reflects a genuine, disclosed multi-channel, multi-phrasing search effort for desvenlafaxine specifically in every category above (zero-result PubMed searches for desvenlafaxine paired with mitochondria, copper, ATP/energy metabolism, anemia, restless legs, and iron are each recorded in their respective entries), not a search that was never attempted. The five categories resting on Tier C extrapolation reflect a genuine literature gap for desvenlafaxine itself, which is a newer and far less studied compound than its parent drug, not a tooling failure specific to this review.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, class/metabolite extrapolation only, no desvenlafaxine-specific data located

Yellow — Low

See study details

This review located no study of any kind testing desvenlafaxine itself against mitochondrial structure, membrane integrity, electron transport, or biogenesis; the entry is carried forward at yellow strictly because venlafaxine, desvenlafaxine's own parent compound and same-class member, has real, drug-specific (though direction-mixed) Tier B mitochondrial evidence in the companion dossier.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No desvenlafaxine-specific mitochondrial study, positive or negative, was located in this review at any tier.
  • At-risk subgroups: Cannot be determined; no human or desvenlafaxine-specific animal data located.

Regulatory status

Not addressed in the label reviewed.

Population evidence

A dedicated PubMed search for "desvenlafaxine mitochondria" returned zero results in this review. The Tier C evidence this entry rests on is venlafaxine's own data, cited in the companion venlafaxine dossier: Scaini G et al, Acta Neuropsychiatrica 2011 (chronic rat dosing, increased respiratory-chain activity, title/listing-confirmed) and Ahmadian E et al, Advanced Pharmaceutical Bulletin 2016 (isolated rat hepatocytes, complex II/IV impairment, title/listing-confirmed). Neither study tested desvenlafaxine as the administered compound.

Mechanism

Not established for desvenlafaxine. If venlafaxine's own mixed-direction mitochondrial signal is at least partly attributable to its circulating desvenlafaxine metabolite (a plausible but untested hypothesis, since desvenlafaxine is present at substantial concentrations after venlafaxine dosing), it would apply to desvenlafaxine-as-administered too, but no source located in this review isolated desvenlafaxine's own contribution from venlafaxine's in either the chronic in vivo or isolated-hepatocyte model.

Counter-evidence held on record

This is one of the entries in this dossier furthest removed from direct evidence; it is retained at yellow rather than ungraded solely because the metabolite relationship to a real, drug-specific class member (venlafaxine) satisfies this project's Tier C class-extrapolation bar, and that basis, not desvenlafaxine-specific data, is stated plainly here. Shares its underlying extrapolated evidence base with the ATP production entry below; see Overlap map. No mitochondrial-support supplement (CoQ10, L-carnitine, or similar) recommendation follows from this entry.

  • PubMed search-listing page, query "desvenlafaxine microbiome," and separately "desvenlafaxine antimicrobial." — Directly opened for each query. "Desvenlafaxine microbiome" (2 results) surfaced Zhao S et al, Nutrition Reviews 2025 (probiotics-versus-antidepressants network meta-analysis, not desvenlafaxine-stratified) and Serrano-Contreras JI et al, Journal of Pharmaceutical and Biomedical Analysis 2016 (venlafaxine-specific rat metabonomics, not desvenlafaxine). "Desvenlafaxine antimicrobial" (23 results) surfaced no study testing desvenlafaxine's direct antimicrobial activity; incidentally surfaced the two Bachmeier transporter studies and the two Dai/Song GI motility studies cited above.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, two independent drug-specific mouse studies, both protective/antioxidant in direction

Yellow — Low

See study details

Two independent research groups found desvenlafaxine itself, not merely its parent compound, associated with increased brain antioxidant markers and reduced lipid peroxidation in separate mouse models, a real, drug-specific, and internally consistent signal, though animal-only and mechanistic rather than a measured change in human antioxidant or nutrient status.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No human oxidative-stress study of desvenlafaxine was located in this review. No study located measured whether this protective animal-model signal translates into any measurable change in human oxidative-stress or antioxidant-nutrient (vitamin C, vitamin E, glutathione precursor) status.
  • At-risk subgroups: Cannot be determined from mouse seizure and depression models; no human data located.

Regulatory status

Not addressed in the label reviewed.

Population evidence

Alharbi KS, "Anticonvulsant effects of desvenlafaxine on modulating brain monoamine and oxidative stress in mice," Brazilian Journal of Biology 2023, DOI 10.1590/1519-6984.246194, confirmed via the Crossref API with abstract text retrieved. Mice, desvenlafaxine succinate tested across multiple doses against pentylenetetrazole, strychnine, pilocarpine, and maximal-electroshock seizure models; desvenlafaxine "increased seizure latency and reduced mortality" and "significantly elevated brain superoxide dismutase, glutathione, and GABA levels while reducing lipid peroxidation," with no motor-coordination impairment on rotarod testing. Silva MC, Sousa CNS, and 9 further co-authors (Federal University of Ceara, Brazil), "Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice," Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015 (in press 2016), PMID 26265141, confirmed via the OpenAlex API with abstract-level summary retrieved, full text not independently opened during this review. Mice, a depression model, hippocampus/striatum/prefrontal cortex; desvenlafaxine and lipoic acid each associated with protective effects against oxidative damage, measured via superoxide dismutase, glutathione metabolism, and lipid peroxidation markers, direction consistent with the Alharbi 2023 findings.

Mechanism

Not established as a single unified pathway across the two studies; both are consistent with an indirect, stress- or seizure-activity-mediated reduction in oxidative burden (via desvenlafaxine's serotonergic/noradrenergic antidepressant and anticonvulsant actions) rather than a direct antioxidant chemistry of the desvenlafaxine molecule itself, since neither study isolated a cell-free or enzyme-level direct antioxidant mechanism.

Counter-evidence held on record

Both sources point in the same, protective direction, which is itself worth flagging as different from venlafaxine's own oxidative-stress entry in the companion dossier, where two studies ran in opposite directions; this should not be read as desvenlafaxine being "safer" for oxidative stress than venlafaxine in humans, since neither drug has a human oxidative-stress outcome study, only as an accurate record of what each drug's own animal literature currently shows. No antioxidant-supplement recommendation (vitamin C, vitamin E, N-acetylcysteine, or similar) follows from this entry in either direction.

  • PubMed search-listing page, query "desvenlafaxine oxidative stress." — Directly opened. Surfaced Alharbi KS, Brazilian Journal of Biology 2023 (desvenlafaxine-specific, mouse seizure model); Silva MC et al, Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015/2016 (desvenlafaxine-specific, mouse depression model); Mihai DP et al, International Journal of Molecular Sciences 2021 (venlafaxine, risperidone, and febuxostat tested, not desvenlafaxine itself, despite desvenlafaxine being mentioned in discussion as venlafaxine's metabolite, so not used as supporting evidence here); and several chemical stability-testing papers not biologically relevant.
  • Alharbi KS. Anticonvulsant effects of desvenlafaxine on modulating brain monoamine and oxidative stress in mice. — Mouse, desvenlafaxine succinate, multiple seizure models (Tier B, drug-specific). Confirmed via the Crossref API with abstract text retrieved (bibliographic API lookup, not the publisher's own article page). Primary source for the Oxidative stress entry: increased brain superoxide dismutase, glutathione, and GABA; reduced lipid peroxidation; increased seizure latency and reduced mortality; no rotarod motor impairment.
  • Silva MC, Sousa CNS, and colleagues. Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice. — Mouse, desvenlafaxine and lipoic acid, depression model, hippocampus/striatum/prefrontal cortex (Tier B, drug-specific). Confirmed via the OpenAlex API with abstract-level summary retrieved.Full text and full abstract were not independently opened during this review after Europe PMC and a direct PubMed article-page fetch were both rate-limited or blocked; used at OpenAlex abstract-summary level only.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper, class/metabolite extrapolation only, no desvenlafaxine-specific data located

Yellow — Low

See study details

No study located in this review tested desvenlafaxine against any copper-related endpoint; a dedicated PubMed search for "desvenlafaxine copper" returned zero results, and this entry is carried forward at yellow strictly as a Tier C extrapolation from venlafaxine's own rat Cu/Zn-superoxide dismutase finding in the companion dossier.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No desvenlafaxine-specific copper study, positive or negative, was located in this review at any tier.
  • At-risk subgroups: Cannot be determined; no desvenlafaxine-specific data located.

Regulatory status

Not addressed in the label reviewed; no copper-specific interaction, monitoring requirement, or warning exists in the labeling reviewed.

Population evidence

A dedicated PubMed search for "desvenlafaxine copper" returned zero results in this review. The Tier C evidence this entry rests on is venlafaxine's own data, cited in the companion venlafaxine dossier: Xu H, Chen Z, He J, Haimanot S, Li X, Dyck L, Li XM, "Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus," Neuropsychopharmacology 2003 (rat, chronic dosing, venlafaxine among the antidepressants tested per PubMed search-listing, direction of the Cu/Zn-SOD change not confirmed in either dossier). This review's own drug-specific oxidative-stress evidence for desvenlafaxine (Alharbi 2023, Silva 2016, see Oxidative stress entry above) measured general superoxide dismutase activity but did not isolate the copper-zinc isoform or measure serum or tissue copper status, so it is not used as supporting evidence here; see Overlap map.

Mechanism

Cu/Zn-SOD (SOD1) requires copper as an active-site cofactor; a change in the enzyme's expression, if it occurred with desvenlafaxine as it may have with venlafaxine, would be an indirect marker of altered cellular copper handling, not a direct measurement of whole-body or serum copper status. No source located in this review measured serum copper, ceruloplasmin, or dietary copper status for either drug.

Counter-evidence held on record

This is among the weakest entries in this dossier: it rests on a single venlafaxine source whose own direction of effect could not be confirmed in the companion dossier either, now extrapolated a further step to a different (though closely related) molecule. No copper supplementation or restriction is implied by this entry.

Iron, class extrapolation only, a multi-step inference further attenuated than venlafaxine's own already-caveated entry

Yellow — Low

See study details

No study located in this review associated desvenlafaxine itself with periodic limb movements, restless-legs-type symptoms, or any iron-status measure; a dedicated PubMed search for "desvenlafaxine restless legs" and "desvenlafaxine iron" each returned zero results, and this entry is carried forward at yellow only because venlafaxine, its own parent compound, has real human comparative data on this association, itself only weakly and indirectly connected to iron status.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No desvenlafaxine-specific restless-legs, periodic-limb-movement, or iron-status study, positive or negative, was located in this review at any tier.
  • At-risk subgroups: Cannot be determined; no desvenlafaxine-specific data located.

Regulatory status

Not addressed in the label reviewed; restless legs syndrome and periodic limb movements are not listed as labeled adverse reactions for desvenlafaxine in the sections reviewed.

Population evidence

A dedicated PubMed search for "desvenlafaxine restless legs" returned zero results in this review, and a separate search for "desvenlafaxine iron" also returned zero results (a Crossref API search using the same terms surfaced only unrelated pharmacopeial monographs and pediatric iron-deficiency reviews, none involving desvenlafaxine). The Tier C evidence this entry rests on is venlafaxine's own data, cited in the companion venlafaxine dossier: Yang C, White DP, Winkelman JW, "Antidepressants and periodic leg movements of sleep," Biological Psychiatry 2005 (human, n=274, polysomnography, title/listing-confirmed, venlafaxine specifically implicated) and Kouri I et al, "Restless Legs Syndrome and Periodic Limb Movements of Sleep: From Neurophysiology to Clinical Practice," Journal of Clinical Neurophysiology 2023, which per its PubMed search-listing snippet noted "higher rates for mirtazapine and venlafaxine," naming venlafaxine specifically but not desvenlafaxine or SNRIs as a class.

Mechanism

Not established for desvenlafaxine at any step. The inference chain is now one step longer than venlafaxine's own already-caveated entry: (1) venlafaxine, not desvenlafaxine, is associated with periodic limb movements/restless-legs-type symptoms in human comparative sleep-study data; (2) restless legs syndrome's general pathophysiology (unrelated to either drug) implicates CNS iron insufficiency; (3) it is proposed, but not demonstrated anywhere in the literature located in this review, that this could extend to desvenlafaxine via the metabolite/class relationship. None of the three steps was directly tested for desvenlafaxine.

Counter-evidence held on record

This is the weakest entry in this dossier: it is a three-step inference built entirely on the parent drug's data, with no desvenlafaxine-specific evidence at any step, retained at yellow only because the underlying class member (venlafaxine) has real human data and the project's grading rule permits class extrapolation from any real class member's data, not because this review found anything pointing toward iron specifically for desvenlafaxine. This entry must never be read as "desvenlafaxine causes iron deficiency" or even as "desvenlafaxine causes restless legs symptoms," a finding this review did not confirm for desvenlafaxine itself. No iron supplementation is recommended from this entry; a patient developing new restless-legs symptoms on desvenlafaxine warrants clinical evaluation rather than self-directed iron supplementation.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, drug-specific motility evidence plus class extrapolation for composition change

Yellow — Low

See study details

Two dog studies found desvenlafaxine itself slows gastric motility and transit via a sympathetic mechanism, a real, drug-specific, and mechanistically plausible but indirect pathway to microbiome disruption, while the direct evidence for actual gut microbiome composition change (in vitro antimicrobial activity, animal composition-change studies) comes only from venlafaxine, not desvenlafaxine, in this review.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No human or animal gut-microbiome-composition study of desvenlafaxine specifically was located in this review; a dedicated PubMed search for "desvenlafaxine microbiome" returned two results, neither of which tested desvenlafaxine directly (one was a probiotics-versus-antidepressants network meta-analysis not drug-level stratified for desvenlafaxine, the other a venlafaxine-specific rat urine/faeces metabonomic study). A further search for "desvenlafaxine antimicrobial" returned 23 results, none of which tested desvenlafaxine's direct antimicrobial activity against bacteria.
  • At-risk subgroups: Cannot be determined from dog motility data or from venlafaxine's extrapolated composition data alone.

Regulatory status

Not addressed in the label reviewed.

Population evidence

Dai F, Lei Y, Chen JD, "Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions, and gastric accommodation mediated via the sympathetic mechanism in dogs," American Journal of Physiology, Gastrointestinal and Liver Physiology 2011;301(4):G707-12, PMID 21757637, confirmed via PubMed search-listing with abstract-level summary. Song J, Yin J, Chen JD, "Acute and chronic effects of desvenlafaxine on gastrointestinal transit and motility in dogs," Neurogastroenterology and Motility 2013;25(10):824-e637, PMID 23865827, confirmed via PubMed search-listing. Both drug-specific (Tier B, dog model) and directly relevant to gastrointestinal function, but neither measured microbiome composition, diversity, or a functional microbiome marker. The direct microbiome-composition evidence (an in vitro antimicrobial screening study and several animal gut-composition-change studies) cited in the companion venlafaxine dossier tested venlafaxine, not desvenlafaxine, and is carried here only as Tier C class/metabolite extrapolation: venlafaxine is a real class member (and desvenlafaxine's own parent compound) with real supporting data, but desvenlafaxine's own structure (an O-demethylated, non-methylated metabolite) differs enough from venlafaxine's that direct antimicrobial activity, if it is structure-dependent, cannot be assumed to transfer without its own testing.

Mechanism

Slowed gastric and intestinal transit is a well-established general route to altered gut microbial composition (via altered substrate availability, transit-dependent bacterial overgrowth risk, and changed luminal pH and motility-dependent mucus dynamics), but this was not directly tested for desvenlafaxine in either dog study, which measured motility and myoelectric activity, not microbiota.

Counter-evidence held on record

This entry deliberately separates what is actually drug-specific for desvenlafaxine (motility inhibition in dogs) from what is only class/metabolite-extrapolated (composition change, from venlafaxine); a reader should not treat the motility finding as proof of a microbiome effect, since no study located in this review connected the two directly for either drug. No probiotic or microbiome-support supplement recommendation follows from this entry.

  • Dai F, Lei Y, Chen JD. Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions, and gastric accommodation mediated via the sympathetic mechanism in dogs. — Dog, desvenlafaxine succinate, GI motility (Tier B, drug-specific). Confirmed via PubMed search-listing with abstract-level summary.Full text not opened during this review; used at title/search-listing-confirmed level only.
  • Song J, Yin J, Chen JD. Acute and chronic effects of desvenlafaxine on gastrointestinal transit and motility in dogs. — Dog, desvenlafaxine, GI transit (Tier B, drug-specific). Confirmed via PubMed search-listing with abstract-level summary.Full text not opened during this review; used at title/search-listing-confirmed level only.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery / utilization, class/metabolite extrapolation only, explicitly not confirmed in desvenlafaxine's own label or postmarketing data

Yellow — Low

See study details

Venlafaxine's own FDA label lists anemia at an uncommon frequency and rare blood dyscrasias including aplastic anemia in postmarketing data, but desvenlafaxine's own label contains no hematologic adverse reaction of any kind, and a dedicated PubMed search for desvenlafaxine and anemia returned zero results, so this entry is carried forward only as a disclosed, unconfirmed class/metabolite-level extrapolation, not drug-specific evidence.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: The absence of any hematologic signal in desvenlafaxine's own label and in two independent consumer compilations of that label, despite the drug being on the US market since 2008, is itself a genuine null finding, recorded here rather than silently treated as "insufficient data." This review cannot determine whether the absence reflects a true pharmacological difference from venlafaxine, a smaller and more recent postmarketing exposure base for a less-prescribed drug, or reporting/surveillance variance, and does not assert any one of those explanations as established.
  • At-risk subgroups: Not defined for desvenlafaxine beyond the label's general bleeding-risk cautions (concurrent aspirin, NSAIDs, warfarin, or other antiplatelet/anticoagulant therapy).

Regulatory status

Desvenlafaxine's own label (Section 6.1 adverse-reaction tables and "Other Adverse Reactions Observed" list, and Section 6.2 Postmarketing Experience in full) contains no hematologic term (no anemia, leukopenia, thrombocytopenia, agranulocytosis, aplastic anemia, or pancytopenia); Section 6.2 lists only Stevens-Johnson syndrome, acute pancreatitis, Takotsubo cardiomyopathy, and anosmia/hyposmia. This was independently cross-checked against drugs.com's and RxList's consumer compilations of the same FDA labeling, neither of which lists anemia or blood dyscrasias for desvenlafaxine (drugs.com lists only nonspecific "abnormal bleeding," "unusual bleeding or bruising," "blood in stool or urine," and "nosebleeds," each without a stated frequency, under its bleeding-risk content, matching Section 5.4 of the label rather than a distinct hematologic-outcome signal).

Population evidence

None specific to desvenlafaxine was located. The class/metabolite-level evidence this entry rests on is venlafaxine's own labeled data (reviewed and cited in the companion venlafaxine dossier): clinical-trial frequency category "Uncommon (0.1% to 1%): Anemia" and postmarketing "blood dyscrasias (including agranulocytosis, aplastic anemia, neutropenia and pancytopenia)." A dedicated PubMed search for "desvenlafaxine anemia" and, separately, "desvenlafaxine hemoglobin," returned zero results in this review.

Mechanism

Not established for desvenlafaxine directly. If real, the plausible pathway would mirror venlafaxine's: serotonin-transporter-mediated platelet dysfunction contributing to chronic occult blood loss (a mechanism both drugs' labels document under bleeding risk, Section 5.4), or idiosyncratic immune-mediated bone-marrow suppression. Neither mechanism has been demonstrated to produce a measurable hematologic effect for desvenlafaxine specifically in any source located in this review.

Counter-evidence held on record

This entry exists specifically to prevent silent inheritance of venlafaxine's orange grade for this category; the desvenlafaxine-specific evidence base for a hematologic effect is, on the record located in this review, empty, and the grade here reflects only mechanistic plausibility from the parent-drug relationship, not a confirmed desvenlafaxine finding. No iron or other supplementation is implied by this entry. Unexplained fatigue, pallor, easy bruising, or bleeding on desvenlafaxine warrants a complete blood count under medical supervision, exactly as it would for any patient with such symptoms, rather than any assumption drawn from this entry either way.

ATP production, class/metabolite extrapolation only, no desvenlafaxine-specific data located

Yellow — Low

See study details

No study located in this review measured ATP yield, cellular respiration, or energy-substrate balance after desvenlafaxine administration specifically; this entry is carried forward at yellow strictly as a Tier C extrapolation from venlafaxine's own metabolomic energy-substrate finding in the companion dossier.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No desvenlafaxine-specific ATP or energy-metabolism study, positive or negative, was located in this review at any tier.
  • At-risk subgroups: Cannot be determined; no desvenlafaxine-specific data located.

Regulatory status

Not addressed in the label reviewed.

Population evidence

A dedicated PubMed search combining "desvenlafaxine," "ATP," "energy," and "metabolism" returned zero results in this review. The Tier C evidence this entry rests on is venlafaxine's own data, cited in the companion venlafaxine dossier: Brivio P, Audano M, Gallo MT, et al, "Venlafaxine's effect on resilience to stress is associated with a shift in the balance between glucose and fatty acid utilization," Neuropsychopharmacology 2023;48(10):1475-1483 (rat, chronic stress model, ventral hippocampus metabolomics). Venlafaxine was the administered compound in that study, not desvenlafaxine.

Mechanism

Not established for desvenlafaxine. As with Mitochondrial burden above, any contribution of circulating desvenlafaxine to venlafaxine's own observed substrate-shift effect is plausible given the metabolite relationship but was not isolated or tested in the source study.

Counter-evidence held on record

This entry rests entirely on the metabolite/class relationship to venlafaxine's own single metabolomic study, itself an indirect substrate-balance endpoint rather than a direct ATP measurement; two layers of inference (venlafaxine's substrate shift, then extrapolated to desvenlafaxine) separate this entry from a direct finding. No energy-support supplement recommendation (CoQ10, creatine, B-vitamins for energy metabolism, or similar) follows from this entry. See Overlap map for the shared evidence basis with Mitochondrial burden.

How the body handles this medication

Metabolism (simpler and non-CYP2D6-dependent, unlike venlafaxine's activation step)
"Desvenlafaxine is primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism. CYP3A4 mediates the oxidative metabolism (N-demethylation) of desvenlafaxine. The CYP2D6 metabolic pathway is not involved," and "the pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype." This directly contrasts with venlafaxine, whose own activation to desvenlafaxine is CYP2D6-catalyzed and therefore phenotype-dependent; desvenlafaxine, already the active moiety, carries no equivalent activation-step variability.FDA, PRISTIQ full prescribing information, accessdata.fda.gov, 021992s051lbl.pdf, Section 12.3
CYP and transporter effects (absent, a second point of contrast with venlafaxine)
"Desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, 2C19, CYP2D6, or CYP3A4 isozymes. Desvenlafaxine does not induce CYP3A4 either," and "desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein (P-gp) transporter." An independent in vitro study of human brain microvascular endothelial cells found venlafaxine, but not desvenlafaxine, induced expression of the P-gp and BCRP drug-efflux transporters; a later in vivo follow-up from the same group found "venlafaxine, and to a lesser extent desvenlafaxine" induced these transporters, a smaller effect for desvenlafaxine than for its parent drug across both studies.FDA, PRISTIQ prescribing information, Section 12.3; Bachmeier CJ et al, Biopharm Drug Dispos 2011;32(4), PMID confirmed via PubMed search-listing; Bachmeier C et al, J Pharm Sci 2013;102(10), title/listing-confirmed
Absorption / route
Oral, absolute bioavailability approximately 80%. "Ingestion of a high-fat meal (800 to 1000 calories) increased desvenlafaxine Cmax about 16% and had no effect on AUC." No chelation, gastric-pH-dependent, bile-acid-sequestration, or named-transporter absorption-interference mechanism (Step 2A) is identified in the label. Separately, two dog studies (not human, not a nutrient-absorption study) found desvenlafaxine inhibits gastric slow waves, antral contractions, and gastric accommodation and slows GI transit via a sympathetic mechanism, a real but indirect, non-graded PK-adjacent finding disclosed in the Headline and the Gut microbiome entry rather than treated as a nutrient-absorption mechanism on its own.FDA, PRISTIQ prescribing information, Section 12.3; Dai F, Lei Y, Chen JD, Am J Physiol Gastrointest Liver Physiol 2011;301(4):G707-12; Song J, Yin J, Chen JD, Neurogastroenterol Motil 2013;25(10):824-e637
Elimination
Terminal half-life approximately 10 hours; volume of distribution 3.4 L/kg; plasma protein binding low (30%), concentration-independent. "Approximately 45% of desvenlafaxine is excreted unchanged in urine at 72 hours after oral administration. Approximately 19% of the administered dose is excreted as the glucuronide metabolite and less than 5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine," a markedly higher fraction of unchanged renal excretion than venlafaxine's roughly 5%, consistent with desvenlafaxine's simpler, largely non-oxidative disposition.FDA, PRISTIQ prescribing information, Section 12.3
Renal / hepatic impairment
Moderate renal impairment (CrCl 30 to 50 mL/min): maximum 50 mg daily. Severe renal impairment or ESRD (CrCl less than 30 mL/min): "25 mg every day or 50 mg every other day." Moderate to severe hepatic impairment: "the recommended dose... is 50 mg per day. Dose escalation above 100 mg per day is not recommended." Both reflect desvenlafaxine's dependence on renal clearance of unchanged drug and hepatic conjugation capacity, not a direct nutrient-handling effect.FDA, PRISTIQ prescribing information, Section 2
Dilutional/hormonal disturbance (mechanism present, drives the Sodium entry)
"Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)... Cases with serum sodium lower than 110 mmol/L have been reported." Elderly patients, and patients taking diuretics or otherwise volume-depleted, are stated to be at greater risk. This is a retention/dilutional disturbance, not a dietary depletion, and per this project's framing rule is graded on the same tier scale but never implies sodium supplementation as a remedy (see Sodium entry).FDA, PRISTIQ prescribing information, Section 5.9
Dose-related blood pressure and appetite/weight effects (mechanism clarification and intake-reduction context, not standalone nutrient entries)
"Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies," with sustained hypertension (SDBP 90 mmHg or more and 10 mmHg or more above baseline) observed in 1.3 to 2.3% of patients across dose groups; per Hard Rule 2 this is desvenlafaxine's own noradrenergic pharmacodynamic action, not a nutrient it depletes, and is carried into the Monitoring panel rather than graded. Separately, "decreased appetite" and "decreased weight" are each listed as common (1 to 10% incidence) adverse reactions, with mean weight reductions of 0.4 to 1.1 kg across dose groups in controlled trials, a general reduced-intake mechanism (Step 2H) not linked in this review to any specific graded nutrient and noted in the Monitoring panel instead.FDA, PRISTIQ prescribing information, Section 5.3 and Section 6.1
All references used above
  1. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, N06AX23 Desvenlafaxine. — Confirms ATC classification (N06AX23, "Other antidepressants" group) and DDD (50 mg, oral), matching the label's recommended dose. Directly opened and read.
  2. FDA. PRISTIQ (desvenlafaxine) extended-release tablets, full prescribing information. — FDA label (Tier A). Directly opened and read via WebFetch. Primary source for Section 12.3 Pharmacokinetics (bioavailability, UGT-mediated conjugation, CYP2D6 non-involvement, CYP3A4 non-induction, P-gp non-substrate status, half-life, protein binding, urinary recovery percentages, food effect), Section 2 renal and hepatic dose adjustment, Section 5.1 through 5.11 in full (suicidality, serotonin syndrome, blood pressure, bleeding, angle closure glaucoma, mania, discontinuation syndrome, seizure, hyponatremia, interstitial lung disease, sexual dysfunction), Section 6.1 adverse reactions and laboratory changes (lipids, proteinuria), and Section 6.2 Postmarketing Experience in full.
  3. FDA. PRISTIQ prescribing information, earlier revision. — FDA label (Tier A). Directly opened and read via WebFetch. Cross-checked against the 2023 revision for Section 12.3 pharmacokinetics and Section 2 dosing; content consistent between revisions.
  4. DailyMed. Desvenlafaxine Extended-Release Tablets (Lupin Pharmaceuticals, Inc.), SPL. — FDA label (Tier A), generic manufacturer SPL mirroring the reference listed drug's labeling. Directly opened and read via WebFetch. Cross-checked Section 6.2 Postmarketing Experience and Section 5.9 hyponatremia text against the accessdata.fda.gov labels; content consistent. Also used to confirm the roster of generic desvenlafaxine manufacturers listed under Brands in the masthead.
  5. PubMed search-listing page, query "desvenlafaxine hyponatremia." — Directly opened. Surfaced Viramontes TS, Truong H, Linnebur SA, The Consultant Pharmacist 2016 (review); Garakani A, Primary Care Companion for CNS Disorders 2018 (tramadol-associated case, not used as primary evidence); Lee GT, Leung JL, General Hospital Psychiatry 2013 (first reported desvenlafaxine-specific SIADH case); Liew ED, Alderman CP, International Journal of Clinical Pharmacy 2014 (desvenlafaxine-specific SIADH case). Primary source, at title/search-listing-confirmed level, for the Sodium entry's Tier B case-report evidence.Full text of the two case reports was not opened during this review; used at title/search-listing-confirmed level only.
  6. PubMed search-listing page, query "desvenlafaxine oxidative stress." — Directly opened. Surfaced Alharbi KS, Brazilian Journal of Biology 2023 (desvenlafaxine-specific, mouse seizure model); Silva MC et al, Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015/2016 (desvenlafaxine-specific, mouse depression model); Mihai DP et al, International Journal of Molecular Sciences 2021 (venlafaxine, risperidone, and febuxostat tested, not desvenlafaxine itself, despite desvenlafaxine being mentioned in discussion as venlafaxine's metabolite, so not used as supporting evidence here); and several chemical stability-testing papers not biologically relevant.
  7. Alharbi KS. Anticonvulsant effects of desvenlafaxine on modulating brain monoamine and oxidative stress in mice. — Mouse, desvenlafaxine succinate, multiple seizure models (Tier B, drug-specific). Confirmed via the Crossref API with abstract text retrieved (bibliographic API lookup, not the publisher's own article page). Primary source for the Oxidative stress entry: increased brain superoxide dismutase, glutathione, and GABA; reduced lipid peroxidation; increased seizure latency and reduced mortality; no rotarod motor impairment.
  8. Silva MC, Sousa CNS, and colleagues. Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice. — Mouse, desvenlafaxine and lipoic acid, depression model, hippocampus/striatum/prefrontal cortex (Tier B, drug-specific). Confirmed via the OpenAlex API with abstract-level summary retrieved.Full text and full abstract were not independently opened during this review after Europe PMC and a direct PubMed article-page fetch were both rate-limited or blocked; used at OpenAlex abstract-summary level only.
  9. PubMed search-listing page, query "desvenlafaxine anemia," and separately "desvenlafaxine mitochondria," "desvenlafaxine copper," "desvenlafaxine ATP energy metabolism," "desvenlafaxine restless legs." — Directly opened for each query. Each search independently confirmed to return "No results were found" with meta-log_resultcount 0, forming the basis for this dossier's repeated, disclosed zero-result findings for desvenlafaxine specifically in the Oxygen delivery/utilization, Mitochondrial burden, Copper, ATP production, and Iron entries above.
  10. Dai F, Lei Y, Chen JD. Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions, and gastric accommodation mediated via the sympathetic mechanism in dogs. — Dog, desvenlafaxine succinate, GI motility (Tier B, drug-specific). Confirmed via PubMed search-listing with abstract-level summary.Full text not opened during this review; used at title/search-listing-confirmed level only.
  11. Song J, Yin J, Chen JD. Acute and chronic effects of desvenlafaxine on gastrointestinal transit and motility in dogs. — Dog, desvenlafaxine, GI transit (Tier B, drug-specific). Confirmed via PubMed search-listing with abstract-level summary.Full text not opened during this review; used at title/search-listing-confirmed level only.
  12. Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. — Human brain microvascular endothelial cells, in vitro (Tier B, both drugs directly compared). Confirmed via PubMed search-listing. Primary source for the Pharmacokinetic basis transporter-induction contrast between venlafaxine and desvenlafaxine.Full text not opened during this review; used at title/search-listing-confirmed level only.
  13. Bachmeier C, Levin GM, Beaulieu-Abdelahad D, Reed J, Mullan M. Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. — In vivo follow-up to the 2011 in vitro study (Tier B, both drugs directly compared). Confirmed via PubMed search-listing. Found "venlafaxine, and to a lesser extent desvenlafaxine" induced P-gp and BCRP.Full text not opened during this review; used at title/search-listing-confirmed level only.
  14. PubMed search-listing page, query "desvenlafaxine microbiome," and separately "desvenlafaxine antimicrobial." — Directly opened for each query. "Desvenlafaxine microbiome" (2 results) surfaced Zhao S et al, Nutrition Reviews 2025 (probiotics-versus-antidepressants network meta-analysis, not desvenlafaxine-stratified) and Serrano-Contreras JI et al, Journal of Pharmaceutical and Biomedical Analysis 2016 (venlafaxine-specific rat metabonomics, not desvenlafaxine). "Desvenlafaxine antimicrobial" (23 results) surfaced no study testing desvenlafaxine's direct antimicrobial activity; incidentally surfaced the two Bachmeier transporter studies and the two Dai/Song GI motility studies cited above.
  15. Drugs.com. Pristiq side effects page. — Consumer drug-information source compiling FDA labeling. Directly opened. Source for cross-checking the Oxygen delivery/utilization entry's absence of hematologic adverse-reaction content, the labeled decreased-appetite/decreased-weight/lipid content, the rare (less than 0.1%) hyponatremia frequency category, and the circulating-claim audit (no nutrient-depletion content found).
  16. RxList. Pristiq drug page. — Consumer drug-information source. Directly opened. Reviewed for the circulating-claim audit (no nutrient, vitamin, or mineral depletion content found) and cross-checked hematologic/bleeding and hyponatremia content against DailyMed and the FDA label.
  17. Access-limited channels, disclosed across this review.The Europe PMC REST API (www.ebi.ac.uk/europepmc/webservices/rest/) and Semantic Scholar Graph API (api.semanticscholar.org) returned HTTP 429 rate-limit responses or proxy-level 403 rejections on nearly every attempt throughout this review, across every category, not just one. The OpenAlex API (api.openalex.org) succeeded on at least one query (the Silva 2016 abstract-level lookup above) but was rejected on others. The Crossref API (api.crossref.org) was the most reliable of the four bibliographic APIs and is the backbone of several citations above. Individual PubMed article pages (pubmed.ncbi.nlm.nih.gov/[PMID]/) intermittently returned a Google reCAPTCHA bot-verification challenge rather than content, while PubMed's own search-listing pages (pubmed.ncbi.nlm.nih.gov/?term=...) worked reliably for the large majority of attempts and are the backbone of this review's citations. This review's WebSearch tool allowance was exhausted before a small number of secondary confirmatory queries, including a brand-name history check, could be completed, after which all further research used WebFetch against PubMed search-listing pages, DailyMed, accessdata.fda.gov, the Crossref and OpenAlex APIs, and drugs.com/RxList.